#ViiV Healthcare

Nearly $200 million of the pledge will go to DREAMS programs in Africa and the Caribbean.

ViiV Healthcare and GlaxoSmithKline are jointly developing GSK3640254.

Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.

The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.

Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.

Dovato (dolutegravir/lamivudine) is the second approved two-antiretroviral regimen.

Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.

PACHA had been empty over a year, after everyone quit or was fired by Trump.

Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.

Previous studies found Tivicay monotherapy was subpar, but this trial switched people to the drug who had started combo treatment early.

Fostemsavir offers HIV treatment hope to those with no other options.

Here are the top 20 philanthropic funders of HIV, according to an FCAA report, which also offers good news for the U.S. South and PrEP.

However, the regimen appears much less potent for those who aren’t virally suppressed.